SCHEMBL3075965

SCHEMBL3075965

COC(=O)c1nc2cccc(CO)c2[nH]1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.39
ALDH1A1 P00352 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
MAPT P10636 4/20 0.39
HSD17B10 Q99714 2/20 0.39
TNKS O95271 1/20 0.38
LMNA P02545 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
HPGD P15428 2/20 0.37
PKM P14618 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
RXFP1 Q9HBX9 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GABRP O00591 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31569165 0.82 PIN1 (0.40) KDM4EALDH1A1SMN1; SMN2MAPTLMNA
SCHEMBL24113223 0.79 NR4A2 (0.48) KDM4EALDH1A1SMN1; SMN2MAPTHSD17B10
SCHEMBL55693 0.79 ALDH1A1 (0.44) KDM4EALDH1A1SMN1; SMN2MAPTHSD17B10
SCHEMBL31568995 0.79 MAPT (0.44) KDM4EALDH1A1SMN1; SMN2MAPTHSD17B10
SCHEMBL31569227 0.76 KDM4E (0.42) KDM4EALDH1A1SMN1; SMN2MAPTHSD17B10
SCHEMBL28791191 0.75 TDP1 (0.41) KDM4EALDH1A1MAPTLMNAPKM
SCHEMBL24020357 0.74 MMP13 (0.39) KDM4EALDH1A1SMN1; SMN2LMNANPC1
SCHEMBL14162132 0.73 PARP1 (0.43) KDM4ESMN1; SMN2NPC1RAB9AMEN1
SCHEMBL29468653 0.73 TNKS (0.42) KDM4EALDH1A1SMN1; SMN2MAPTHSD17B10
SCHEMBL10662224 0.73 GAA (0.37) KDM4EALDH1A1SMN1; SMN2MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025101780-A1 PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF OCTANT, INC. (US) 2025-05-15 WO disclosed
US-7842688-B2 Organic compounds NOVARTIS PHARMA AG (CH) 2010-11-30 US disclosed
US-7790715-B2 Organic compounds NOVARTIS AG (CH) 2010-09-07 US disclosed
US-20090012055-A1 Organic compounds HEROLD PETER 2009-01-08 US disclosed
EP-1961752-A2 Piperidine Compounds Speedel Experimenta AG (CH) 2008-08-27 EP disclosed
US-20070010511-A1 Organic compounds NOVARTIS PHARMA AG (CH) 2007-01-11 US disclosed
EP-1707202-A1 Organic compounds Speedel Experimenta AG (CH) 2006-10-04 EP disclosed
EP-1670760-A1 ORGANIC COMPOUNDS Speedel Experimenta AG (CH) 2006-06-21 EP disclosed
WO-2005061457-A1 ORGANIC COMPOUNDS SPEEDEL EXPERIMENTA AG (CH) 2005-07-07 WO disclosed
WO-2005061457-A1 ORGANIC COMPOUNDS SPEEDEL EXPERIMENTA AG (CH) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012055-A1 Organic compounds REN, ACE, ACE2 KDM4E 1843/4885ALDH1A1 142/4885SMN1; SMN2 4291/4885
US-20070010511-A1 Organic compounds REN, ACE, ACE2 KDM4E 1843/4885ALDH1A1 142/4885SMN1; SMN2 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.